onychopharma_anti_fiungi_treatment_foot_

A Multi-focused Mode of Action

OnychoPharma Graphics-11.png
  • In-vitro data has demonstrated activity against Propiones acne, a bacteria dependent on oxygen
     

  • The patented processing method releases several fatty acids with anti-microbial activity.

  • Hydrolysis of the β -1,4 linkages between the glucosamine/acetyl glucosamine sub-units of the polymer due to a chitinase or chitosanase and thereby kills the fungus.

  • Reduces SLS-induced release of a pro-inflammatory cytokine (IL-1 alpha) after 6 hours exposure
     

  • No cytotoxic / irritating effect on skin

  • Stimulates growth of skin-derived cells (e.g., keratinocytes) with 24-hours by up to 29%
     

  • Stimulates protein neosynthesis in keratinocytes with the highest effect (+26%) after 48-hours.

onychopharma_anti_fiungi_treatment_foot_

Publication

A pilot single centre, double blind, placebo controlled, randomized, parallel study of Calmagen® dermaceutical cream and lotion for the topical treatment of tinea and onychomycosis.
Parekh et al. BMC Complement Altern Med. 2017;17(1):464. Published 2017 Sep 18. doi:10.1186/s12906-017-1970-2

A double-blind randomised controlled study performed to assess the mycological cure rates of tinea and onychomycosis infections with the application of Amycot topical cream. To determine the cure rates a KOH smear, fungal culture and live spore count were performed. At screening visits, 100% of patients were positive for KOH smear and received daily topical application of Amycot cream (or placebo). At study end, 13 of 14 (92.86%) patients in the Amycot® arm were negative to infection vs. no (0%) of the patients in the placebo arm (p < 0.0001). Clinical cure was achieved for all subjects receiving Amycot® whilst none in the placebo arm were clinically cured. No adverse events were reported in the Amycot® arm whilst 1 patient reported mild pain in both the legs (not related to the study medication) in the placebo group.